UA101057C2 - Pyrimidine derivatives as kinase inhibitors - Google Patents
Pyrimidine derivatives as kinase inhibitorsInfo
- Publication number
- UA101057C2 UA101057C2 UAA201104068A UAA201104068A UA101057C2 UA 101057 C2 UA101057 C2 UA 101057C2 UA A201104068 A UAA201104068 A UA A201104068A UA A201104068 A UAA201104068 A UA A201104068A UA 101057 C2 UA101057 C2 UA 101057C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pyrimidine derivatives
- kinase inhibitors
- analplastic
- igf
- alk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin- like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7558308P | 2008-06-25 | 2008-06-25 | |
PCT/US2009/048428 WO2010002655A2 (en) | 2008-06-25 | 2009-06-24 | Compounds and compositions as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
UA101057C2 true UA101057C2 (en) | 2013-02-25 |
Family
ID=41076758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201104068A UA101057C2 (en) | 2008-06-25 | 2009-06-24 | Pyrimidine derivatives as kinase inhibitors |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2331526A2 (en) |
JP (1) | JP2011526291A (en) |
KR (1) | KR20110020940A (en) |
CN (1) | CN102203083A (en) |
AU (1) | AU2009262198B2 (en) |
BR (1) | BRPI0914545A2 (en) |
CA (1) | CA2729546A1 (en) |
EA (1) | EA201100078A1 (en) |
MX (1) | MX2010014568A (en) |
UA (1) | UA101057C2 (en) |
WO (1) | WO2009158431A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
WO2011018517A1 (en) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
KR102012057B1 (en) * | 2011-11-29 | 2019-08-19 | 제넨테크, 인크. | Aminopyrimidine derivatives as lrrk2 modulators |
AU2013344049B2 (en) | 2012-11-06 | 2017-12-21 | Fochon Pharmaceuticals, Ltd. | ALK kinase inhibitors |
EP2970205B1 (en) * | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
EP3150592B1 (en) * | 2014-05-30 | 2023-08-30 | Shanghai Emerald Wellcares Pharmaceutical Co., LTD | Alk kinase inhibitor, and preparation method and use thereof |
US10377743B2 (en) * | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
CN107488148A (en) * | 2017-06-26 | 2017-12-19 | 安徽省黄淮兽药有限公司 | A kind of hydrocinnamamide insecticides and preparation method thereof |
WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
TW202045008A (en) * | 2019-02-01 | 2020-12-16 | 印度商皮埃企業有限公司 | 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds, preparation and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
DK1656372T3 (en) * | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINE DIAMINE COMPOUNDS FOR USING TREATMENT OR PREVENTION OF AUTO-IMMUNE DISEASES |
ES2365223T3 (en) * | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | 2,4-PYRIMIDINDIAMINE COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS. |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
US8211929B2 (en) * | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
US8222256B2 (en) * | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
UA100846C2 (en) * | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Compounds and compositions as protein kinase inhibitors |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
CN101952275B (en) * | 2008-02-22 | 2014-06-18 | 弗·哈夫曼-拉罗切有限公司 | Modulators for amyloid protein beta |
-
2009
- 2009-06-24 JP JP2011516619A patent/JP2011526291A/en not_active Ceased
- 2009-06-24 MX MX2010014568A patent/MX2010014568A/en not_active Application Discontinuation
- 2009-06-24 EP EP09770964A patent/EP2331526A2/en not_active Withdrawn
- 2009-06-24 BR BRPI0914545A patent/BRPI0914545A2/en not_active IP Right Cessation
- 2009-06-24 AU AU2009262198A patent/AU2009262198B2/en not_active Expired - Fee Related
- 2009-06-24 CN CN200980129584XA patent/CN102203083A/en active Pending
- 2009-06-24 UA UAA201104068A patent/UA101057C2/en unknown
- 2009-06-24 KR KR1020117001749A patent/KR20110020940A/en not_active Application Discontinuation
- 2009-06-24 CA CA2729546A patent/CA2729546A1/en not_active Abandoned
- 2009-06-24 WO PCT/US2009/048509 patent/WO2009158431A2/en active Application Filing
- 2009-06-24 EA EA201100078A patent/EA201100078A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2729546A1 (en) | 2009-12-30 |
JP2011526291A (en) | 2011-10-06 |
MX2010014568A (en) | 2011-03-29 |
WO2009158431A2 (en) | 2009-12-30 |
EP2331526A2 (en) | 2011-06-15 |
CN102203083A (en) | 2011-09-28 |
KR20110020940A (en) | 2011-03-03 |
WO2009158431A3 (en) | 2010-03-11 |
AU2009262198A1 (en) | 2009-12-30 |
BRPI0914545A2 (en) | 2017-05-23 |
AU2009262198B2 (en) | 2012-09-27 |
EA201100078A1 (en) | 2011-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010002655A3 (en) | Pyrimidine derivatives as kinase inhibitors | |
MX2010002336A (en) | Compounds and compositions as kinase inhibitors. | |
UA101057C2 (en) | Pyrimidine derivatives as kinase inhibitors | |
UA100846C2 (en) | Compounds and compositions as protein kinase inhibitors | |
TN2009000225A1 (en) | Compounds and compositions as protein kinase kinase inhibitors | |
MX2010010968A (en) | Compounds and compositions as protein kinase inhibitors. | |
WO2009126514A8 (en) | Compounds and compositions as kinase inhibitors | |
MX2012000711A (en) | Pyrrolopyrazine inhibitors of kinases. | |
MX2009000884A (en) | Pyridizinone derivatives. | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
MX2012013197A (en) | Indazole inhibitors of kinase. | |
MX2012000709A (en) | Pyrrolopyridine inhibitors of kinases. | |
MX2011013325A (en) | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors. | |
MX336726B (en) | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors. | |
AU2011276193A8 (en) | Bipyridyl derivatives useful for the treatment of kinase - induced diseases | |
MX2009004140A (en) | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors. | |
TN2011000207A1 (en) | Akt and p70 s6 kinase inhibitors | |
MX2011012632A (en) | Pyrimidine inhibitors of kinase activity. | |
MX2011012629A (en) | Pyrimidine inhibitors of kinase activity. | |
MX2011012631A (en) | Pyrimidine inhibitors of kinase activity. | |
WO2009094560A3 (en) | Thienopyranones as kinase inhibitors | |
WO2010039668A3 (en) | Inhibitors of cyclin kinase inhibitor p21 | |
MX2009012079A (en) | Condensed heterocyclic compounds as inhibitors of protein kinases. | |
MX2009003793A (en) | Kinase inhibitors. | |
TN2010000602A1 (en) | Pyrimidine derivatives as kinase inhibitors |